Clincosm LogoSign in Get a demo

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Sponsor
Tiziana Life Sciences, PLC (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT05029609
Collaborator
(none)
0
Enrollment
4
Arms
14
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses for 14 consecutive days.

Condition or Disease Intervention/Treatment Phase
  • Drug: Intranasal Foralumab Solution
  • Drug: Placebo
 Phase 1

Detailed Description

This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS.

Up to 55 untreated primary and secondary progressive MS patients will be enrolled, to obtain a total of 48 completed subjects (9 active, 3 placebos per group), allowing for dropouts.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS.This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS
Anticipated Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Group A

Group A will receive nasal Foralumab Dose 1 daily for 14 days (n=9) or placebo (n=3)

Drug: Intranasal Foralumab Solution
The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Drug: Placebo
The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Other: Group B

Group B will receive nasal Foralumab Dose 2 tiw for 14 days (n=9) or placebo (n=3)

Drug: Intranasal Foralumab Solution
The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Drug: Placebo
The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Other: Group C

Group C will receive nasal Foralumab Dose 3 daily for 14 days (n=9) or placebo (n=3)

Drug: Intranasal Foralumab Solution
The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Drug: Placebo
The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
Other: Group D

Group D will receive nasal Foralumab Dose 4 daily for 14 days (n=9) or placebo (n=3)

Drug: Intranasal Foralumab Solution
The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

Drug: Placebo
The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.

Outcome Measures

Primary Outcome Measures

  1. To establish the safety of intranasal foralumab in non-active primary and secondary progressive MS in escalating doses for 14 consecutive days [14 days]

    Analyses through review of adverse events categorized and graded via CTCAE.

Secondary Outcome Measures

  1. Change in Expanded Disability Status Scale (EDSS) at Day 45 [45 days]

    The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. EDSS steps 1.0 to 4.5 refer to people with MS who are able to walk without any aid and is based on measures of impairment in eight functional systems. Lower score indicates that the subject is doing better.

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Confirmed diagnosis of MS (according to the 2010 McDonald criteria).

  2. Age 25-70 years.

  3. Clinical diagnosis of non-active primary and secondary MS

  4. MRI imaging consistent with a diagnosis of MS at any time point.

  5. Score on the Expanded Disability Status Scale (EDSS) of 2.5-6.5

  6. Adequate hematologic parameters without ongoing transfusion support:

  • Hemoglobin (Hb) ≥ 9 g/dL

  • Platelets ≥ 100 x 109 cells/L

  1. Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance

≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula

  1. Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease

  2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN, or < 5 times ULN for patients with liver metastases

  3. QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening

  4. Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP)

  5. Ability to provide written informed consent.

Exclusion Criteria:

  1. Corticosteroid use (oral or intravenous) within the last 30 days.

  2. Current use or use in the prior 6 months of MS immunotherapy, interferon, glatiramer acetate, fingolimod, siponimod, dimethyl fumarate or natalizumab or any other chronic immunosuppressive medication

  3. Inability to tolerate intranasally administered medications

  4. Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days.

  5. Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 12 months.

  6. Active COVID-19 disease; according to FDA guidelines

  7. Female patient who is pregnant, lactating, breastfeeding, or planning on becoming pregnant during study.

  8. Female patients of childbearing age will undergo a pregnancy test and be excluded from the study if positive.

  9. Active malignancy within 5 years.

  10. Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, asthma, or type 1 diabetes

  11. Neutropenia (<500 neutrophils/mL) or other severe immunosuppression

  12. Unable or unwilling to comply with protocol requirements.

  13. Patients with a history of gadolinium allergy.

  14. Screening labs outside of the normal range; EBV IgM positive subjects with clinical signs will not receive study drug.

  15. Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV (See Appendix B) or hereditary long QT syndrome

  16. Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care

  17. Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)

  18. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Tiziana Life Sciences, PLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tiziana Life Sciences, PLC
ClinicalTrials.gov Identifier:
NCT05029609
Other Study ID Numbers:
  • TILS-015
First Posted:
Aug 31, 2021
Last Update Posted:
Mar 3, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Neoplasm Metastasis
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Sclerosis

Study Results

No Results Posted as of Mar 3, 2022